GMXAY
GENMAB A/S/S ADR

55
Mkt Cap
$18.82B
Volume
1.16M
52W High
$33.65
52W Low
$17.24
PE Ratio
12.88
GMXAY Fundamentals
Price
$30.04
Prev Close
$30.57
Open
$30.72
50D MA
$30.12
Beta
0.58
Avg. Volume
2.69M
EPS (Annual)
$1.77
P/B
3.27
Rev/Employee
$1.16M
Loading...
Loading...
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
2,682

Frequently Asked Questions

What is Market Cap of Genmab - ADR?
What is the 52-week high for Genmab - ADR?
What is the 52-week low for Genmab - ADR?
What is Genmab - ADR stock price today?
What was Genmab - ADR stock price yesterday?
What is the PE ratio of Genmab - ADR?
What is the Price-to-Book ratio of Genmab - ADR?
What is the 50-day moving average of Genmab - ADR?
How many employess does Genmab - ADR has?

Latest GMXAY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.